Literature DB >> 12522068

Up-regulation of kinin B1 receptor in the lung of streptozotocin-diabetic rat: autoradiographic and functional evidence.

Rose Mari J Vianna1, Brice Ongali, Domenico Regoli, João Batista Calixto, Réjean Couture.   

Abstract

1 The function and autoradiographic binding expression of kinin B(1) receptors were evaluated in the lungs of Streptozotocin (STZ)-diabetic rats. 2 The intrapleural injection (i.pl.) of des-Arg(9)-bradykinin (des-Arg(9)-BK) (50 and 100 nmol per site), a selective B(1) receptor agonist, increased time-dependently the mononuclear and neutrophil cells influx in the pleural cavity of rats treated with STZ (65 mg kg(-1), i.p., 4 days earlier). This effect was significantly less in control rats. 3 The influx of mononuclear and polymorphonuclear neutrophil cells induced by des-Arg(9)-BK was significantly inhibited by two B(1) receptor antagonists (des-Arg(10)-Hoe140 or R-715, 100 nmol per site, 5 min earlier), but not by two B(2) receptor antagonists (Hoe140, 10 nmol or NPC 18884, 100 nmol per site, 5 min earlier). However, Hoe140 prevented the higher basal leukocyte influx seen in STZ-diabetic rats. 4 Leukocyte infiltration induced by des-Arg(9)-BK in STZ-diabetic rats was significantly reduced after treatment with insulin (2 U per day, s.c. over 4 days) or with an anti-PMN antibody (0.1 ml of a 1 : 20 dilution, i.pl. 5 min earlier). 5 Specific B(1) receptor binding sites were seen in lung sections from both control and STZ-diabetic rats, yet the density of labelling was much greater in diabetic rats and particularly after intrapleural injection of des-Arg(9)-BK. Treatment with insulin or with the anti-PMN antibody markedly reduced B(1) receptor binding sites occurring after the injection of des-Arg(9)-BK in STZ-diabetic rats. 6 Data suggest that the B(1) receptor is up-regulated in the lungs of STZ-diabetic rats, and its activation increases leukocyte infiltration into the pleural cavity. The overexpression of B(1) receptors seems to depend on neutrophils influx and appears to be associated with hyperglycaemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522068      PMCID: PMC1573626          DOI: 10.1038/sj.bjp.0704999

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Altered neutrophil homeostasis in kinin B1 receptor-deficient mice.

Authors:  R C Araújo; R Kettritz; I Fichtner; A C Paiva; J B Pesquero; M Bader
Journal:  Biol Chem       Date:  2001-01       Impact factor: 3.915

2.  DesArg9-D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist.

Authors:  K Wirth; G Breipohl; J Stechl; J Knolle; S Henke; B Schölkens
Journal:  Eur J Pharmacol       Date:  1991-11-26       Impact factor: 4.432

3.  Structure-activity studies of B1 receptor-related peptides. Antagonists.

Authors:  F Gobeil; W Neugebauer; C Filteau; D Jukic; S N Allogho; L H Pheng; X K Nguyen-Le; D Blouin; D Regoli
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

Review 4.  The B1 receptors for kinins.

Authors:  F Marceau; J F Hess; D R Bachvarov
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

5.  Effects of captopril and Icatibant on bradykinin (BK) and des [Arg9] BK in carrageenan-induced edema.

Authors:  A Decarie; A Adam; R Couture
Journal:  Peptides       Date:  1996       Impact factor: 3.750

6.  Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation.

Authors:  Marilyne Mage; Christiane Pécher; Eric Neau; Eric Cellier; Marina L Dos Reiss; Joost P Schanstra; Réjean Couture; Jean-Loup Bascands; Jean-Pierre Girolami
Journal:  Can J Physiol Pharmacol       Date:  2002-04       Impact factor: 2.273

7.  Changes in paw oedema triggered via bradykinin B(1) and B(2) receptors in streptozotocin-diabetic rats.

Authors:  M M Campos; D A Cabrini; A H Cardozo; G A Rae; J H Toro; J B Calixto
Journal:  Eur J Pharmacol       Date:  2001-03-23       Impact factor: 4.432

8.  Oral anti-inflammatory action of NPC 18884, a novel bradykinin B2 receptor antagonist.

Authors:  T S Saleh; R M Vianna; T B Creczynski-Pasa; S Chakravarty; B J Mavunkel; D J Kyle; J B Calixto
Journal:  Eur J Pharmacol       Date:  1998-12-18       Impact factor: 4.432

9.  Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation.

Authors:  P Raymond; G Drapeau; R Raut; R Audet; F Marceau; H Ong; A Adam
Journal:  J Immunol Methods       Date:  1995-03-27       Impact factor: 2.303

10.  Mediation by B1 and B2 receptors of vasodepressor responses to intravenously administered kinins in anaesthetized dogs.

Authors:  N Nakhostine; C Ribuot; D Lamontagne; R Nadeau; R Couture
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more
  10 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

Review 2.  Pulmonary vascular dysfunction in metabolic syndrome.

Authors:  Conor Willson; Makiko Watanabe; Atsumi Tsuji-Hosokawa; Ayako Makino
Journal:  J Physiol       Date:  2018-09-12       Impact factor: 5.182

3.  Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw.

Authors:  R Medeiros; G F Passos; C E Vitor; J Koepp; T L Mazzuco; L F Pianowski; M M Campos; J B Calixto
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

4.  Retinal plasma extravasation in streptozotocin-diabetic rats mediated by kinin B(1) and B(2) receptors.

Authors:  M Abdouh; S Talbot; R Couture; H M Hasséssian
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

5.  B1 and B2 kinin receptor blockade improves psoriasis-like disease.

Authors:  Bruna da Silva Soley; Leonardo Martins Silva; Daniel Augusto Gasparin Bueno Mendes; André Báfica; João Bosco Pesquero; Michael Bader; Deborah A Witherden; Wendy L Havran; João B Calixto; Michel Fleith Otuki; Daniela Almeida Cabrini
Journal:  Br J Pharmacol       Date:  2020-05-30       Impact factor: 8.739

6.  Activation of kinin B1 receptor evokes hyperthermia through a vagal sensory mechanism in the rat.

Authors:  Sébastien Talbot; Helaine De Brito Gariépy; Julien Saint-Denis; Réjean Couture
Journal:  J Neuroinflammation       Date:  2012-09-13       Impact factor: 8.322

7.  Effects of a novel bradykinin B1 receptor antagonist and angiotensin II receptor blockade on experimental myocardial infarction in rats.

Authors:  Dongmei Wu; Xinchun Lin; Christian Bernloehr; Tobias Hildebrandt; Henri Doods
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

8.  Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats.

Authors:  Mylène Pouliot; Sébastien Talbot; Jacques Sénécal; Florence Dotigny; Elvire Vaucher; Réjean Couture
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

9.  Cellular localization of kinin B1 receptor in the spinal cord of streptozotocin-diabetic rats with a fluorescent [Nalpha-Bodipy]-des-Arg9-bradykinin.

Authors:  Sébastien Talbot; Patrick Théberge-Turmel; Dalinda Liazoghli; Jacques Sénécal; Pierrette Gaudreau; Réjean Couture
Journal:  J Neuroinflammation       Date:  2009-03-26       Impact factor: 8.322

10.  In Vivo Anti-Diabetic Activity of the Ethanolic Crude Extract of Sorbus decora C.K.Schneid. (Rosacea): A Medicinal Plant Used by Canadian James Bay Cree Nations to Treat Symptoms Related to Diabetes.

Authors:  Rose Vianna; Antoine Brault; Louis C Martineau; Réjean Couture; John T Arnason; Pierre S Haddad
Journal:  Evid Based Complement Alternat Med       Date:  2011-08-11       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.